Veranova, a developer and manufacturer of specialist and complex APIs for the pharmaceutical and biotech sectors, has moved its corporate headquarters to its Devens, Massachusetts facility, one of the company’s principal sites for manufacturing and development.

About the Devens Site

Strategically located near the Boston pharmaceutical and biotech hub, Veranova’s Devens site is an FDA approved facility and a center of excellence for development through clinical and commercial manufacturing of antibody-drug conjugates (ADCs), high potent APIs, phosphoramidites and other complex small molecules. The site is currently undergoing a $30 million expansion of its ADC and high potent development and manufacturing capabilities.

The investment in Devens is part of a multi-year growth strategy to build the leading development and manufacturing partner for complex synthetic pharmaceuticals, and spans the company’s locations in West Deptford, New Jersey; North Andover, Massachusetts; Edinburgh, Scotland and Cambridge, England.

With the re-location of the corporate headquarters, Veranova will be exiting the current headquarters office in Wayne, Pennsylvania. Existing employees in Wayne will continue operating from a new location in Berwyn, Pennsylvania.

More Veranova News

Last year, Veranova appointed Cécile Maupas as Senior Vice President, Chief Commercial Officer.